Novel therapies and ongoing trials in NHL: advances in antibody-based combinations
In this discussion, Laurie Sehn, MD, MPH, BC Cancer Agency, Vancouver, Canada, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, and Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discuss novel therapies being explored for the treatment of non-Hodgkin lymphoma (NHL). The experts discuss trials investigating tafasitamab (L-MIND: NCT02399085; InMIND: NCT04680052), the antibody-drug conjugates loncastuximab tesirine and polatuzumab vedotin, and share their perspectives on the most exciting therapies in the pipeline. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.